Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.

ABSTRACT:

Background

Phase II clinical trials are a cornerstone of the development in experimental treatments They work as a "filter" for phase III trials confirmation. Surprisingly the attrition ratio in Phase III trials in oncology is significantly higher than in any other medical specialty. This suggests phase II trials in oncology fail to achieve their goal. Objective The present study aims at estimating the quality of reporting in published oncology phase II clinical trials.

Data sources

A literature review was conducted among all phase II and phase II/III clinical trials published during a 5-year period (2010-2015).

Study eligibility criteria

All articles electronically published by three randomly-selected oncology journals with Impact-Factors>4 were included: Journal of

SUBMITTER: Langrand-Escure J 

PROVIDER: S-EPMC5720777 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature